Matriptase-dependent epidermal pre-neoplasm in zebrafish embryos caused by a combination of hypotonic stress and epithelial polarity defects.
Journal
PLoS genetics
ISSN: 1553-7404
Titre abrégé: PLoS Genet
Pays: United States
ID NLM: 101239074
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
04
04
2023
accepted:
17
07
2023
revised:
23
08
2023
medline:
24
8
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
epublish
Résumé
Aberrantly up-regulated activity of the type II transmembrane protease Matriptase-1 has been associated with the development and progression of a range of epithelial-derived carcinomas, and a variety of signaling pathways can mediate Matriptase-dependent tumorigenic events. During mammalian carcinogenesis, gain of Matriptase activity often results from imbalanced ratios between Matriptase and its cognate transmembrane inhibitor Hai1. Similarly, in zebrafish, unrestrained Matriptase activity due to loss of hai1a results in epidermal pre-neoplasms already during embryogenesis. Here, based on our former findings of a similar tumor-suppressive role for the Na+/K+-pump beta subunit ATP1b1a, we identify epithelial polarity defects and systemic hypotonic stress as another mode of aberrant Matriptase activation in the embryonic zebrafish epidermis in vivo. In this case, however, a different oncogenic pathway is activated which contains PI3K, AKT and NFkB, rather than EGFR and PLD (as in hai1a mutants). Strikingly, epidermal pre-neoplasm is only induced when epithelial polarity defects in keratinocytes (leading to disturbed Matriptase subcellular localization) occur in combination with systemic hypotonic stress (leading to increased proteolytic activity of Matriptase). A similar combinatorial effect of hypotonicity and loss of epithelial polarity was also obtained for the activity levels of Matriptase-1 in human MCF-10A epithelial breast cells. Together, this is in line with the multi-factor concept of carcinogenesis, with the notion that such factors can even branch off from one and the same initiator (here ATP1a1b) and can converge again at the level of one and the same mediator (here Matriptase). In sum, our data point to tonicity and epithelial cell polarity as evolutionarily conserved regulators of Matriptase activity that upon de-regulation can constitute an alternative mode of Matriptase-dependent carcinogenesis in vivo.
Identifiants
pubmed: 37566613
doi: 10.1371/journal.pgen.1010873
pii: PGENETICS-D-23-00375
pmc: PMC10446194
doi:
Substances chimiques
matriptase
EC 3.4.21.-
Proteinase Inhibitory Proteins, Secretory
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010873Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM063904
Pays : United States
Organisme : NIGMS NIH HHS
ID : R56 GM063904
Pays : United States
Informations de copyright
Copyright: © 2023 Hatzold et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Biochem J. 2005 Jun 1;388(Pt 2):679-87
pubmed: 15669920
Dev Dyn. 2007 Nov;236(11):3088-99
pubmed: 17937395
Nat Rev Cancer. 2022 Oct;22(10):593-602
pubmed: 35999292
Cancer Res. 2015 Jul 15;75(14):2949-60
pubmed: 26018085
Development. 2009 Apr;136(8):1231-40
pubmed: 19261700
Biochim Biophys Acta. 2014 Jul;1843(7):1285-94
pubmed: 24685580
Curr Opin Nephrol Hypertens. 2008 Sep;17(5):526-32
pubmed: 18695395
Am J Physiol Cell Physiol. 2007 Jul;293(1):C95-105
pubmed: 17344310
J Biol Chem. 2008 Apr 18;283(16):10535-42
pubmed: 18263585
Nat Commun. 2021 Nov 11;12(1):6522
pubmed: 34764253
Int J Dev Biol. 2004;48(2-3):217-31
pubmed: 15272388
Dev Cell. 2010 Jan 19;18(1):25-38
pubmed: 20152175
J Biol Chem. 2002 Mar 22;277(12):10539-46
pubmed: 11792696
J Biol Chem. 2000 Aug 25;275(34):26333-42
pubmed: 10831593
Am J Physiol Renal Physiol. 2005 May;288(5):F923-9
pubmed: 15625083
Elife. 2021 Jun 24;10:
pubmed: 34165081
Development. 2000 May;127(10):2089-98
pubmed: 10769233
Nucleic Acids Res. 2016 Nov 16;44(20):9611-9623
pubmed: 27903883
Trends Genet. 1993 Apr;9(4):138-41
pubmed: 8516849
Am J Physiol Cell Physiol. 2005 Apr;288(4):C932-41
pubmed: 15590895
Exp Cell Res. 2014 Nov 1;328(2):249-57
pubmed: 25179759
Nat Commun. 2015 Apr 15;6:6776
pubmed: 25873032
Semin Cancer Biol. 2012 Jun;22(3):208-15
pubmed: 22465739
J Cell Biol. 2020 Feb 3;219(2):
pubmed: 31819976
Development. 1996 Dec;123:95-102
pubmed: 9007232
J Cell Biol. 2018 Mar 5;217(3):1097-1112
pubmed: 29301867
Oncogene. 2011 Apr 28;30(17):2003-16
pubmed: 21217780
Clin Cancer Res. 2015 Mar 1;21(5):969-75
pubmed: 25573382
PLoS Genet. 2009 Nov;5(11):e1000720
pubmed: 19911055
Nat Rev Cancer. 2013 Sep;13(9):624-36
pubmed: 23969693
Front Endocrinol (Lausanne). 2014 May 13;5:67
pubmed: 24860547
Trends Cell Biol. 2011 Jul;21(7):401-8
pubmed: 21530265
Crit Rev Oncol Hematol. 2015 Oct;96(1):1-8
pubmed: 26070626
Front Physiol. 2019 Feb 26;10:147
pubmed: 30863319
PLoS Genet. 2009 Jul;5(7):e1000563
pubmed: 19609345
Cancer Metastasis Rev. 2019 Sep;38(3):357-387
pubmed: 31529338
Dev Dyn. 2002 Mar;223(2):204-15
pubmed: 11836785
PLoS Genet. 2014 Jul 31;10(7):e1004470
pubmed: 25078604
Int J Cancer. 2017 Jan 1;140(1):130-141
pubmed: 27615543
J Biochem. 2010 Apr;147(4):485-92
pubmed: 19919953
Dev Dyn. 2011 Jan;240(1):278-87
pubmed: 21181945
Acta Biochim Biophys Sin (Shanghai). 2007 May;39(5):384-90
pubmed: 17492136
Oncogene. 2003 Dec 18;22(58):9225-30
pubmed: 14681682
Genes Dev. 2005 Aug 15;19(16):1934-50
pubmed: 16103220
J Biol Chem. 2003 Jul 18;278(29):26773-9
pubmed: 12738778
PLoS Biol. 2014 May 06;12(5):e1001855
pubmed: 24802997
Am J Physiol Cell Physiol. 2004 May;286(5):C1159-69
pubmed: 15075215
Exp Dermatol. 2007 Apr;16(4):302-10
pubmed: 17359336
Elife. 2016 Jul 15;5:
pubmed: 27421119
J Cell Physiol. 2012 Apr;227(4):1604-9
pubmed: 21678412
Oncogene. 2008 Nov 24;27(55):6888-907
pubmed: 19029932
J Cell Sci. 2007 Oct 1;120(Pt 19):3372-83
pubmed: 17881499
Nature. 2009 Jun 25;459(7250):1141-5
pubmed: 19553998
Cancer Cell. 2012 Nov 13;22(5):601-14
pubmed: 23153534
PLoS Genet. 2014 Jan;10(1):e1004048
pubmed: 24415949
Front Cell Dev Biol. 2021 Aug 03;9:684036
pubmed: 34414180
Nat Rev Cancer. 2021 Jun;21(6):379-392
pubmed: 33727690
Dev Biol. 2006 Jun 1;294(1):148-60
pubmed: 16566913
PLoS One. 2015 Jun 25;10(6):e0130688
pubmed: 26110643
J Mol Biol. 2018 Sep 28;430(19):3585-3612
pubmed: 29409995
Biochem J. 2010 Jun 15;428(3):325-46
pubmed: 20507279
Mol Med. 2006 Jan-Mar;12(1-3):1-7
pubmed: 16838070
EMBO J. 2015 Sep 2;34(17):2219-36
pubmed: 26136213
PLoS One. 2023 Jan 30;18(1):e0267492
pubmed: 36716335
J Cell Sci. 2017 Jan 1;130(1):269-277
pubmed: 27149923
Cold Spring Harb Perspect Med. 2020 Aug 3;10(8):
pubmed: 31615862
PLoS One. 2014 Apr 04;9(4):e93899
pubmed: 24705933
Oncol Rep. 2021 Dec;46(6):
pubmed: 34608498
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5771-6
pubmed: 17389401
Semin Cell Dev Biol. 2012 Oct;23(8):890-6
pubmed: 22960184
PLoS One. 2014 Nov 05;9(11):e112183
pubmed: 25372289
J Exp Med. 2017 Feb;214(2):339-358
pubmed: 28096290
PLoS One. 2014 May 29;9(5):e98186
pubmed: 24873830
Biol Open. 2016 Oct 15;5(10):1380-1387
pubmed: 27543057
Development. 2009 Aug;136(15):2591-600
pubmed: 19570844
Oncogene. 2020 Nov;39(47):7019-7033
pubmed: 32999444
Am J Pathol. 2001 Apr;158(4):1301-11
pubmed: 11290548
Clin Exp Metastasis. 2002;19(7):639-49
pubmed: 12498394
Development. 2005 Jul;132(14):3255-65
pubmed: 15983403
Development. 2007 Oct;134(19):3461-71
pubmed: 17728346
J Biol Chem. 2004 Apr 30;279(18):18592-9
pubmed: 14982936
Dev Dyn. 2005 Feb;232(2):359-68
pubmed: 15614774
Cytotechnology. 2009 Apr;59(3):169-76
pubmed: 19557537
Blood. 2011 Jan 27;117(4):1415-24
pubmed: 21097670
Elife. 2020 Jan 22;9:
pubmed: 31967543
Elife. 2016 May 30;5:
pubmed: 27240166
Curr Opin Cell Biol. 2008 Apr;20(2):227-34
pubmed: 18282696
Development. 1998 Dec;125(23):4655-67
pubmed: 9806915